Sakalová A, Gazová S, Makaiová I
Folia Haematol Int Mag Klin Morphol Blutforsch. 1977;104(1):57-63.
The authors report on findings in long-term therapy made by means of a combination of cyclophosphamide as attack dosis (partially also with polychemotherapy--COP, COPP-scheme) and double plasmapheresis. Since 1967 33 patients have been treated in this way. A group (6 patients) only received cyclophosphamide in a attack therapy of 15...25 mg/5g per body weight; a second group of 14 patients received the same dosis in combination with a double plasmapheresis. The third group of 13 patients in an advanced stage of the illness was treated polychemotherapeutically according to various schemes (COP-cyclophosphamide, vincristine, prednisone; COPP with Natulan) likewise in combination with double plasmapheresis. The observations made for 4 years in the two groups first mentioned showed favourable results in the second group with an average survival time of 35 months. In the third group only experiences of two years can be reported and thus a final answer cannot be given. However, it can already be stated that a clinical success requires the cytostatic therapy to be continued for a long time in combination with plasmapheresis.
作者报告了采用环磷酰胺冲击剂量(部分也采用联合化疗——COP、COPP方案)与双重血浆置换相结合的长期治疗结果。自1967年以来,已有33例患者接受了这种治疗。一组(6例患者)仅在冲击治疗中接受环磷酰胺,剂量为每体重5克15……25毫克;第二组14例患者接受相同剂量的环磷酰胺并联合双重血浆置换。第三组13例处于疾病晚期的患者根据不同方案进行联合化疗(COP——环磷酰胺、长春新碱、泼尼松;COPP联合丙卡巴肼),同样联合双重血浆置换。对上述两组进行的4年观察显示,第二组效果良好,平均生存时间为35个月。在第三组中,仅能报告两年的经验,因此无法给出最终答案。然而,可以指出的是,临床成功需要在进行血浆置换的同时长期持续进行细胞抑制治疗。